2017 Fiscal Year Final Research Report
Candidate biomarkers for predicting drug response in cancer treatment
| Project/Area Number |
15K08109
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小見山 智義 東海大学, 医学部, 准教授 (60439685)
|
|---|
| Research Collaborator |
Yu Shyr Vanderbilt大学, 癌センター, 教授
Hande Kenneth R. Vanderbilt大学, 癌センター, 教授
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | がん / 薬剤反応性 |
|---|
| Outline of Final Research Achievements |
Idarubicin (IDR), which inhibits DNA polymerase, is a key drug to treat leukemia. We investigated the mechanism of resistance using the human leukemia cell line MOLT-3 and its idarubicin-resistant MOLT-3/IDR by mitochondrial DNA and exome nuclear DNA analyses.
In resistant sublines, LIG1 DNA ligase 1 and helicase plurality genes showed amino acid-related changes. Amino acid mutations were also confirmed in polymerase-associated genes. GO enrichment testing was performed and lipid-related genes were selected based on the results. Flow cytometric method was used to determine whether IDR permeability was significantly different in MOLT-3/IDR and MOLT-3. The data showed that an IDR concentration of 0.5 μg resulted in slow permeability in MOLT-3/IDR. The slow IDR permeability seen in MOLT-3/IDR might be due to the effects of the amino acid changes found in polymerase- and lipid-associated genes.
Our findings suggest that multiple mutations in these genes play a role in IDR resistance.
|
| Free Research Field |
臨床薬理学
|
